Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity - Wikidata - awgldk - TriplyDB

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

http://www.wikidata.org/entity/Q28373048

about

Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA)Rimonabant for overweight or obesity Long-term pharmacotherapy for obesity and overweight Obesity: an overview on its current perspectives and treatment options ChemDIS: a chemical–disease inference system based on chemical–protein interactions Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects Extracts from "Clinical Evidence". Obesity.Anti-obesity effects of Lysimachia foenum-graecum characterized by decreased adipogenesis and regulated lipid metabolism.Pharmacological treatment of obesity.Orlistat in the treatment of obesity.Orlistat--a novel weight loss therapy.Sibutramine-associated adverse effects: a practical guide for its safe use.Modafinil decreases food intake in humans subjected to simulated shift work.Chinese slimming capsules containing sibutramine sold over the Internet: a case series Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options.HOX-7 suppresses body weight gain and adipogenesis-related gene expression in high-fat-diet-induced obese mice.Contemporary approaches into obesity: drugs and genes.Veratri Nigri Rhizoma et Radix (Veratrum nigrum L.) and Its Constituent Jervine Prevent Adipogenesis via Activation of the LKB1-AMPKα-ACC Axis In Vivo and In Vitro.Present and future therapeutic strategies in non-alcoholic fatty liver disease.Antiadipogenic Effects of Aster glehni Extract: In Vivo and In Vitro Effects.Obesity: a review of pathogenesis and management strategies.Interaction of Veratrum nigrum with Panax ginseng against Obesity: A Sang-ban Relationship.Polycystic ovary syndrome, obesity and reproductive implications.Identification and determination of synthetic pharmaceuticals as adulterants in eight common herbal weight loss supplements.A review of unmet needs in obesity management.Inhibitory effects of Aster spathulifolius extract on adipogenesis and lipid accumulation in 3T3-L1 preadipocytes.New actions of an old friend: perivascular adipose tissue's adrenergic mechanisms.5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials.Anti-obesity effects of Boussingaulti gracilis Miers var. pseudobaselloides Bailey via activation of AMP-activated protein kinase in 3T3-L1 cells.Anti-Obesity Effects of the Mixture of Eriobotrya japonica and Nelumbo nucifera in Adipocytes and High-Fat Diet-Induced Obese Mice.Psychosis associated with usage of herbal slimming products adulterated with sibutramine: a case series.Sibutramine effects on the reproductive performance of pregnant overweight and non-overweight rats.Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.Effects of sibutramine in non-dieting obese women.Health risks, past usage, and intention to use weight loss products in normal weight women with high and low body dysphoria.Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.Serotonin syndrome following sibutramine poisoning in a child, with sequential quantification of sibutramine and its primary and secondary amine metabolites in plasma.Electrophysiological safety of sibutramine HCl.

P2860

Q22251113-885D70B1-0F0B-4B0F-8DD9-46727F61ED04 Q24244078-89BE4BA9-7CE7-4710-8C85-4B93491DF65D Q24247723-8B0E587C-FCC5-45F3-BE37-C6F764F0DA86 Q24792455-59C388B2-71DC-484E-BF0C-0B2368257D4E Q27902304-AF47D7DF-5353-4FCC-9AB9-696BEF1F0EE9 Q28066691-2A90446A-644B-469E-8715-A8F413DE9DC8 Q29308187-E08E1423-32DD-4164-944B-025BCACC623F Q33805817-3AEC617F-C030-4BA7-8364-B074E4721A92 Q33841823-20A878C6-0CD0-4F8C-AF19-8644EEB3E892 Q33996725-8C6BD51E-09DE-409C-912D-9AC81B13B74F Q34182135-F14C9B4A-3E41-4424-898C-F27F8D793CBA Q34191297-1EA573A5-024C-4871-8C63-6AC458A9F833 Q34585304-531876E2-98BE-44CD-9FF6-39C5E04C175E Q34788366-A8F05B1A-3626-4D33-BF01-D531C92D48B6 Q34983224-D67F6E7A-A9F2-4C3C-AE41-AEC6181E79ED Q35029802-207F2CE4-93C5-4994-B6E8-02A734BFA928 Q35060413-584C7E9F-773E-4D3E-8769-370999D81B23 Q35992004-C7025504-E17C-4736-8CDA-1C9608F7E86F Q36814522-DB8C4508-F65E-4725-A7BC-A15744249F8E Q36936358-1C1106A9-68C6-47FD-801E-82B45318FE8F Q36995285-3E5DBA6C-83A1-4CA7-8D13-E46A2C106016 Q37061997-C38F653D-349B-4819-A314-3ECD4FA9D44E Q37173554-D55031DB-EEBF-4D5B-B1E1-7D1FD43F40CA Q37585306-4D5E6DE4-6207-4B2A-95E4-E8C5B8B1211A Q37733914-37A0B2A6-84EC-4BE8-9FCB-EC5210CE8DCA Q37995983-E577AA4D-391B-4D93-AE52-FF996E356A2C Q38827616-D2ED7DB6-E9C2-42F6-94A5-C7BF924A390C Q38998472-52277C8E-4DC5-4ADC-BEC7-F64A368801D3 Q41980535-A7994AA3-30C2-46AE-9AD0-330B00E93EF0 Q42321603-AE132F66-A4C7-4A20-862F-16736C77B60C Q42825533-D84C3C25-90A5-41E3-830E-D202B16DFBCB Q42850075-39A29FE9-0275-43FE-9158-CC24AE0C5845 Q43011934-70FB0351-6796-43C3-99C3-C3AAE1F10AC6 Q43882700-8166AF33-9410-4D08-BC1A-D88E9860B9E6 Q43882702-82F194EF-33D9-405D-B567-716E546F2A30 Q43944301-E7A17DEA-6B80-4E88-8F34-5C8334F54D60 Q44525141-27B0FEF2-A9E5-4519-AD2D-D8F8F99B18E3 Q45097301-56F0C17B-99D1-4575-809E-152BE875D0C7 Q45935486-3E3DC818-51EC-4A0D-87B5-F93E99D6A7E4 Q46336288-DC342581-8E44-4150-A817-2FFC96315E04

P2860

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

http://www.wikidata.org/entity/Q28373048

description

1999 nî lūn-bûn

@nan

1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@ast

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@en

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@nl

type

label

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@ast

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@en

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@nl

prefLabel

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@ast

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@en

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@nl

P1433

Q28373048-B7E7E2B5-77DB-4F4E-BEEB-DAA9FA5D07E5

P1476

Q28373048-7B6757E4-302B-4368-9A31-A9FE9134CEA3

P2093

Q28373048-25E2BB9C-4F0F-4F92-B120-51544A543F3E

Q28373048-2959A06C-0368-4DD6-AB5F-816A6EA3F1C4

P2860

Q28373048-15D0D1BD-4E75-4BA9-8DF7-C9B65944AD20

Q28373048-181D21D6-3545-45EA-AB77-5EB2C809F124

Q28373048-1D88F764-A0D1-45F0-A4B9-837BB31951E0

Q28373048-207D4FB2-108C-492E-BFE8-8399FD3A000F

Q28373048-241608FC-3E5A-4509-BB09-D0C69CAAE9A6

Q28373048-274FCFF1-A648-4D35-8263-7C33EFBF3974

Q28373048-2822D04C-A9C7-4849-965A-590C4160B707

Q28373048-292EA278-4301-4A5F-923D-38760C16253C

Q28373048-41FE80B4-7B20-496D-81A6-A021FD25E12B

Q28373048-48CB0EAD-ADCF-4B36-BCE8-8EB8F63C5D43

P304

Q28373048-0F123480-C9CC-4C38-A12B-CCD0CFA7AC3A

P31

Q28373048-94CFC6B6-7F31-482F-B827-343A6CFDA1C3

P3181

Q28373048-E3772F86-9552-4C86-A7E9-E269E185131A

P356

Q28373048-DACCCBEE-09E9-4952-8601-AAA0A0D36CA0

P407

Q28373048-964F8F4C-30A5-42E8-8D12-E8BAF71EC077

P433

Q28373048-264462FA-D1B0-4032-B526-3F914883543B

P478

Q28373048-55C32B71-F3AB-47A4-8104-7B156B28630B

P577

Q28373048-8EB7048F-62E4-440C-9716-9A52AC4C9B52

P5875

Q28373048-79198827-6FAB-4223-8C3F-E1275FF80D49

P698

Q28373048-F0E88B6B-F861-44FE-BEA9-94EC15C95DA3

P921

Q28373048-62D28E39-1D3D-4548-ADA1-D202408A1881

Q28373048-8108df2c-1cfa-4b14-bb6b-c30824c2e2c4

Q28373048-c1749496-2681-4e8b-bc66-5c2d046b7538

P3181

P356

P1433

Annals of Pharmacotherapy

P1476

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

@en

P2093

C A Luque

http://www.w3.org/2001/XMLSchema#string

J A Rey

http://www.w3.org/2001/XMLSchema#string

P2860

Valvular heart disease associated with fenfluramine-phentermine

Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.

Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Appetite suppressants. A review.

Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.

Medical hazards of obesity.

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents.

The effects of BTS 54,505, a metabolite of sibutramine, on monoamine and excitatory amino acid-evoked responses in the rat dorsolateral geniculate nucleus in vivo.

Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers.

P304

968-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2445365

http://www.w3.org/2001/XMLSchema#string

P356

10.1345/APH.18319

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

1999-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12806738

http://www.w3.org/2001/XMLSchema#string

P698

10492502

http://www.w3.org/2001/XMLSchema#string

P921